8-K: QT Imaging Holdings Reports Strong Q4 2025 Growth, $39M 2026 Outlook

QT Imaging Holdings, Inc. has posted an investor presentation detailing robust Q4 2025 financial results, a positive 2026 revenue forecast, and key strategic advancements including CPT code approval and international expansion.

Summary

• QT Imaging Holdings, Inc. (QTI) posted an investor presentation on its website on February 25, 2026, providing supplemental product and operational information.
• The company reported Q4 2025 commercial revenue of $8.3 million, representing 877% year-over-year growth and 97% sequential quarter-over-quarter growth.
• For the full year 2025, QTI shipped 40 scanners and generated record revenue of $18.9 million, surpassing its revenue guidance of $18.0 million.
• QTI ended Q4 2025 with $10.5 million in cash, a significant increase from $1.2 million at the end of Q4 2024.
• The company expects 2026 revenue to be approximately $39 million, including scanner shipments and initial revenue from its SaaS Cloud Platform.
• A new Category III CPT code, X579T, for QTI's radiation-free, compression-free, 3D breast imaging platform was approved by the AMA in February 2026, scheduled for release on July 1, 2026, with an effective date of January 1, 2027.
• QTI's technology is FDA cleared for breast imaging and holds Breakthrough Device Designation, providing a fast track to unique CPT codes and future clearances.
• The company has strategic distribution agreements with NXC Imaging (a Canon Medical Systems subsidiary) for the USA market, Gulf Medical for the Kingdom of Saudi Arabia (KSA), and Al Naghi Medical for the United Arab Emirates (UAE), with committed minimum order quantities (MOQs) through 2028.
• The National Institutes of Health (NIH) has awarded QT Imaging approximately $18 million for a supplemental imaging solution for women with dense breasts.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, reflecting significant revenue growth, improved financial health, and strategic advancements in product development and market expansion, despite ongoing net losses.

Positives

• Strong commercial revenue growth: $8.3 million in Q4 2025 (877% YoY, 97% QoQ) and $18.9 million for FY2025, surpassing $18.0 million guidance.
• Significant increase in cash: $10.5 million at Q4 2025, up from $1.2 million at Q4 2024 and $1.7 million at Q3 2025.
• Positive future revenue guidance: Approximately $39 million expected for 2026, including SaaS Cloud Platform revenue.
• FDA clearance for breast imaging and Breakthrough Device Designation, providing a fast track to unique CPT codes and future clearances.
• Approval of Category III CPT code X579T by AMA in February 2026, effective January 1, 2027, recognizing the distinct clinical service of QTI's platform.
• Strategic distribution partnerships with NXC Imaging (USA), Gulf Medical (KSA), and Al Naghi Medical (UAE) with committed MOQs through 2028.
• QTI's technology offers a safe, no-radiation, no-discomfort, high-resolution, and lower-cost alternative to traditional mammography and MRI, especially for women with dense breasts.
• The company is transitioning to a sustainable, data-centric ecosystem with a hardware-plus-SaaS platform and AI-powered biomarkers business model.
• NIH awarded QT Imaging approximately $18 million for a supplemental imaging solution for women with dense breasts.
• Net loss decreased to $1.4 million in Q4 2025 from $3.5 million in Q4 2024.
• Non-GAAP Adjusted EBITDA improved to $(0.4) million in Q4 2025 from $(1.9) million in Q4 2024.

Negatives

• Gross margin declined to 38% in Q4 2025 from 47% in Q4 2024, primarily due to higher manufacturing costs for two scanners attributable to tariffs and other fees.
• The company reported a net loss of $1.4 million in Q4 2025 and $21.1 million for FY2025.
• Cash flows used in operating activities were $9.0 million in 2025.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Risks related to the rollout of QT Imaging Holdings' business and the timing of expected business milestones.
• The demand for QT Imaging Holdings' products and services.
• The ability of QT Imaging Holdings to increase sales of its output products in accordance with its plans.
• Issues that could arise with respect to the manufacture of QT scanners by CMSC.
• The desire of customers and service recipients to continue engaging QT Imaging Holdings.
• The effects of competition on QT Imaging Holdings' future business.
• Changes in the Company’s strategy, future operations, financial positions, and product development timeline.

Future Outlook

QT Imaging Holdings anticipates significant revenue growth in 2026, projecting approximately $39 million, driven by continued scanner shipments and the launch of its SaaS Cloud Platform. The company is also focused on biomarker development, cloud-based AI integration, and clinical decision support tools to enhance its precision imaging platform, with a new CPT code becoming effective in January 2027. Regulatory approvals in Saudi Arabia and UAE are targeted for Q2 and Q3 2026, respectively, with CE Mark expected in Q4 2026.

Management Comments

• "At QT Imaging, we are redefining what's possible in breast imaging delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short."
• "Our goal is to make advanced diagnostic imaging accessible to all women, including those with dense breast tissue or limited access to care."

Industry Context

StockSavvy.ai notes that QT Imaging Holdings is positioning itself to disrupt the $6B+ breast imaging market by offering a non-invasive, radiation-free, and compression-free alternative to mammography and MRI, particularly for women with dense breast tissue. The company's shift towards a hardware-plus-SaaS model with AI-powered biomarkers aligns with broader industry trends emphasizing precision diagnostics, personalized medicine, and cloud-based healthcare solutions, potentially gaining market share from traditional imaging modalities.

Comparison to Industry Standards

• QT Scan offers improved image quality, is safer (no radiation), and provides greater specificity compared to X-Ray Mammography/DBT.
• Unlike handheld ultrasound (HHUS), QT Scan is not operator dependent and provides superior, quantifiable/repeatable image quality.
• Compared to CE-MRI, QT Scan offers high resolution and contrast-to-noise ratio without injections, has lower equipment costs, and requires no special facility or shielding.
• QT Scan avoids the significantly higher radiation exposure of breast CT and does not require contrast agents.
• The average scan time for QT Scan is 10-15 minutes per breast, significantly shorter than CE-MRI (40-45 min), HHUS (30-45 min), and XRM/DBT (15-20 min).
• In a mini-study, QT Scanner identified abnormalities in dense breasts in approximately 84% of cases that were not identified by x-ray mammograms.
• QT Imaging's technology is unique in providing quantitative volumetric maps of speed of sound, attenuation coefficient, and reflection intensity, moving beyond qualitative visual information of traditional methods.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, strategic partnerships, and positive future outlook, but also continued net losses and cash burn from operations.
• Patients: Access to a safe, no-radiation, no-compression, high-resolution breast imaging solution, particularly beneficial for women with dense breasts or those not suitable for mammography.
• Healthcare Providers: New diagnostic tool with potential for higher diagnostic accuracy, reduced recalls, and operator-independent images, integrating with a cloud-based AI platform.
• Employees: Continued growth and development opportunities within a company expanding its product offerings and market reach.

Next Steps

• Deployment of AI/ML models within QTI Cloud SaaS Integration via InteleShares framework.
• Automated pipelines for image reconstruction, feature extraction, and Probability of Cancer Map generation.
• Continuous learning from clinical data uploads and feedback loops for AI.
• FDA validation and CPT reimbursement readiness for clinical decision support tools.
• Cloud-delivered AI updates with no on-premise installs required.
• Regulatory review and expected Marketing Authorization in Saudi Arabia (Q2 2026).
• Dossier preparation and expected approval for UAE MOHAP device registration (Q3 2026).
• Notified Body Engagement and expected CE Mark (EU MDR) (Q4 2026).
• Continued scanner shipments and initial revenue generation from the SaaS Cloud Platform in 2026.
• Category III CPT code X579T becomes effective January 1, 2027.

Key Dates

Recommendation

The company demonstrates significant commercial momentum with impressive year-over-year and sequential revenue growth, exceeding its own guidance. The substantial increase in cash reserves, coupled with a clear path for future revenue generation from both hardware sales and a new SaaS platform, indicates a strong operational trajectory. The FDA Breakthrough Device Designation and the approval of a new Category III CPT code significantly de-risk future reimbursement and market adoption. Strategic international distribution agreements further expand the total addressable market. While the company still reports a net loss and uses cash in operations, the improving EBITDA and clear growth drivers suggest a positive inflection point, making it an attractive investment for long-term growth.

Keywords

Breast imaging, medical device, FDA clearance, ultrasound, dense breast, cancer detection, AI, SaaS, CPT code, QTI, QT Imaging, financial results, investor presentation, healthcare technology